(3S,4S)-Tofacitinib
|
|
(3S,4S)-Tofacitinib 속성
- 밀도
- 1.296
- 저장 조건
- Store at -20°C
- 용해도
- DMSO(약간 용해됨), 메탄올(약간 용해됨)
- 산도 계수 (pKa)
- 6.04±0.60(Predicted)
- 물리적 상태
- 가루
- 색상
- Off-white to pink
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
| 그림문자(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 신호 어: | Warning | |||||||||||||||||||||||||||||||||||
| 유해·위험 문구: |
|
|||||||||||||||||||||||||||||||||||
| 예방조치문구: |
|
(3S,4S)-Tofacitinib C화학적 특성, 용도, 생산
용도
(3S,4S)-Tofacitinib is an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor(CP-690,550).(3S,4S)-Tofacitinib 준비 용품 및 원자재
원자재
준비 용품
(3S,4S)-Tofacitinib 공급 업체
글로벌( 107)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| Hubei Jusheng Technology Co.,Ltd. | 18871490254 |
linda@hubeijusheng.com | CHINA | 28172 | 58 |
| Standardpharm Co. Ltd. | 86-714-3992388 |
overseasales1@yongstandards.com | United States | 14332 | 58 |
| BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19553 | 58 |
| career henan chemical co | +86-0371-86658258 +8613203830695 |
factory@coreychem.com | China | 29815 | 58 |
| Fuxin Pharmaceutical | +86-021-021-50872116 +8613122107989 |
contact@fuxinpharm.com | China | 10032 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 |
marketing@targetmol.com | United States | 32024 | 58 |
| CR Corporation Limited | +8613062833949 |
fred.wen@crcorporation.cn | China | 8647 | 58 |
| Hangzhou Huarong Pharm Co., Ltd. | 571-86758373 +8613588754946 |
sales@huarongpharm.com | CHINA | 3148 | 58 |
| China National Standard Pharmaceutical Corporation Limited | +8615391658522 |
overseasales@yongstandards.com | China | 11922 | 58 |
| LEAPCHEM CO., LTD. | +86-852-30606658 |
market18@leapchem.com | China | 43340 | 58 |
(3S,4S)-Tofacitinib 관련 검색:
(3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine
N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyriMidin-4-yl)(Methyl)aMino)-4-Methylpiperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 19
3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanaMide
6,7-Dihydro-N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-5H-pyrrolo[2,3-d]pyrimidin-4-amine
R-afatinib
Tofacitinib Impurity 20
(S)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diaMine
(3R,4R)-3-[(6-amino-4-pyrimidinyl)methylamino]-4-methyl-β-oxo-1-Piperidinepropanenitrile
(3R,4R)-N,4-dimethyl-piperidin-3-amine
TF-A
2-amino-4-fluoro-5-nitrobenzoic acid
Ethyl S-4-chloro-3-hydroxybutyrate
Tofacitinib Impurity 2
3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity T